– Atlas Health Capital has agreed to acquire AGB-Pharma, a Swedish specialist pharmaceutical company focused on sleep disorders.
– The transaction will be funded through Atlas Health Fund I, which was oversubscribed and raised in early 2026.
– AGB-Pharma was founded in Lund, Sweden, in 2020 and has grown into a European leader in sleep disorder treatments.
– The company follows a patient-centric approach, aiming to improve the quality of life for people living with sleep disorders.
– Atlas Health plans to support the company’s international expansion, product portfolio diversification, and development into a leading pan-European player.
– Atlas Health invests in mid-market European healthcare companies, with a focus on MedTech, Niche Pharma, and Animal Health.
– Managing Partner Ben Long described AGB-Pharma as a strong strategic fit and emphasized plans to invest in the business and expand its capabilities.
– Founder Stig Henningsson highlighted the company’s landmark achievement of securing Sweden’s first approval for Melatonin AGB to treat children with insomnia and ADHD, calling it a major breakthrough for patients and families.
